Serum IL-17 Correlated With Inflammatory Changes in Osteoarthritis and Rheumatoid Arthritis

The total number of the included subjects was 120 in 3 equal groups (RA, OA and control). All subject was subjected to serum IL17 level measurement. MSK US (of both wrists, MCPs, PIPs and DIPs) was done to all patients in RA and OA groups. Disease activity was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis (RA) and Osteoarthritis (OA) Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Osteoarthritis Rheumatic Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Zagazig University Faculty of Medicine

Zagazig, Sharqia Province, 44519, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
A patient is considered having Hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands

Exclusion criteria

Any subject with liver diseases, coronary artery diseases, kidney diseases or other inflammatory conditions was excluded from the study.

Treatment and study plan

Primary outcomes

Clinical disease activity in Rheumatoid Arthritis (RA) and hand Osteoarthritis (OA) patients

Time frame: 12 months

During the whole course of the study, disease activity of the patients was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients.

Secondary outcomes

IL-17 serum levels in RA and OA patients

Time frame: 2 weeks

IL-17 will be measured by enzyme linked immunosorbent assay from collected serum samples from the study participants

Other outcomes

Radiologic bony changes in RA and OA patients

Time frame: 12 months

During the whole course of the study period, recruited participants undergone musculoskeletal (MSK) ultrasound to assess the bony changes.

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

Serum IL-17 Correlated With Inflammatory Changes But Not With Bony Changes in Both Hand Osteoarthritis and Rheumatoid Arthritis

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Jul 17, 2020
Registry last updated: Nov 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed